世界における先天的遺伝子変異または先天的染色体変異検査製品のパイプライン動向2015...市場調査レポートについてご紹介

【英文タイトル】Inborn Gene or Chromosome Alterations - Pipeline Review, 2015

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 5
1.2 List of Figures 10
2 Introduction 11
2.1 Inborn Gene or Chromosome Alterations Overview 11
3 Products under Development 12
3.1 Inborn Gene or Chromosome Alterations – Pipeline Products by Stage of Development 12
3.2 Inborn Gene or Chromosome Alterations – Pipeline Products by Territory 13
3.3 Inborn Gene or Chromosome Alterations – Pipeline Products by Regulatory Path 14
3.4 Inborn Gene or Chromosome Alterations – Pipeline Products by Estimated Approval Date 15
3.5 Inborn Gene or Chromosome Alterations – Ongoing Clinical Trials 16
4 Inborn Gene or Chromosome Alterations – Pipeline Products under Development by Companies 17
4.1 Inborn Gene or Chromosome Alterations Companies – Pipeline Products by Stage of Development 17
4.2 Inborn Gene or Chromosome Alterations – Pipeline Products by Stage of Development 20
5 Inborn Gene or Chromosome Alterations Companies and Product Overview 23
5.1 AC-Gen Reading Life S.L. Company Overview 23
5.1.1 AC-Gen Reading Life S.L. Pipeline Products & Ongoing Clinical Trials Overview 23
5.2 Admera Health, LLC Company Overview 24
5.2.1 Admera Health, LLC Pipeline Products & Ongoing Clinical Trials Overview 24
5.3 Agena Bioscience, Inc Company Overview 25
5.3.1 Agena Bioscience, Inc Pipeline Products & Ongoing Clinical Trials Overview 25
5.4 Ariosa Diagnostics, Inc. Company Overview 29
5.4.1 Ariosa Diagnostics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 29
5.5 Atomic International Company Overview 30
5.5.1 Atomic International Pipeline Products & Ongoing Clinical Trials Overview 30
5.6 Baylor College of Medicine Company Overview 31
5.6.1 Baylor College of Medicine Pipeline Products & Ongoing Clinical Trials Overview 31
5.7 BCML GmbH Company Overview 33
5.7.1 BCML GmbH Pipeline Products & Ongoing Clinical Trials Overview 33
5.8 BioCeps (Inactive) Company Overview 34
5.8.1 BioCeps (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 34
5.9 CardioDx, Inc. Company Overview 35
5.9.1 CardioDx, Inc. Pipeline Products & Ongoing Clinical Trials Overview 35
5.10 Celera Corporation Company Overview 37
5.10.1 Celera Corporation Pipeline Products & Ongoing Clinical Trials Overview 37
5.11 Celula, Inc. Company Overview 41
5.11.1 Celula, Inc. Pipeline Products & Ongoing Clinical Trials Overview 41
5.12 Children’s Hospital Boston Company Overview 42
5.12.1 Children’s Hospital Boston Pipeline Products & Ongoing Clinical Trials Overview 42
5.13 China Medical Technologies, Inc. Company Overview 45
5.13.1 China Medical Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview 45
5.14 Da An Gene Co., Ltd. Company Overview 48
5.14.1 Da An Gene Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview 48
5.15 Dana-Farber Cancer Institute, Inc. Company Overview 51
5.15.1 Dana-Farber Cancer Institute, Inc. Pipeline Products & Ongoing Clinical Trials Overview 51
5.16 Epinex Diagnostics Incorporated Company Overview 53
5.16.1 Epinex Diagnostics Incorporated Pipeline Products & Ongoing Clinical Trials Overview 53
5.17 Genentech, Inc. Company Overview 54
5.17.1 Genentech, Inc. Pipeline Products & Ongoing Clinical Trials Overview 54
5.18 German Cancer Research Center Company Overview 55
5.18.1 German Cancer Research Center Pipeline Products & Ongoing Clinical Trials Overview 55
5.19 GILUPI Nanomedizin Company Overview 57
5.19.1 GILUPI Nanomedizin Pipeline Products & Ongoing Clinical Trials Overview 57
5.20 Hadassah Medical Center Company Overview 58
5.20.1 Hadassah Medical Center Pipeline Products & Ongoing Clinical Trials Overview 58
5.21 Helicos BioSciences Corporation Company Overview 59
5.21.1 Helicos BioSciences Corporation Pipeline Products & Ongoing Clinical Trials Overview 59
5.22 Illumina, Inc. Company Overview 60
5.22.1 Illumina, Inc. Pipeline Products & Ongoing Clinical Trials Overview 60
5.23 IntegraGen SA Company Overview 62
5.23.1 IntegraGen SA Pipeline Products & Ongoing Clinical Trials Overview 62
5.24 Interleukin Genetics, Inc. Company Overview 64
5.24.1 Interleukin Genetics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 64
5.25 JS Genetics Inc. Company Overview 66
5.25.1 JS Genetics Inc. Pipeline Products & Ongoing Clinical Trials Overview 66
5.26 Laboratory Corporation of America Holdings Company Overview 67
5.26.1 Laboratory Corporation of America Holdings Pipeline Products & Ongoing Clinical Trials Overview 67
5.27 Laval University Company Overview 69
5.27.1 Laval University Pipeline Products & Ongoing Clinical Trials Overview 69
5.28 LifeCodexx AG Company Overview 70
5.28.1 LifeCodexx AG Pipeline Products & Ongoing Clinical Trials Overview 70
5.29 Maastricht University Medical Center Company Overview 71
5.29.1 Maastricht University Medical Center Pipeline Products & Ongoing Clinical Trials Overview 71
5.30 Massachusetts Eye and Ear Infirmary Company Overview 72
5.30.1 Massachusetts Eye and Ear Infirmary Pipeline Products & Ongoing Clinical Trials Overview 72
5.31 Medical Research Council Company Overview 74
5.31.1 Medical Research Council Pipeline Products & Ongoing Clinical Trials Overview 74
5.32 Micromedic Technologies Ltd Company Overview 75
5.32.1 Micromedic Technologies Ltd Pipeline Products & Ongoing Clinical Trials Overview 75
5.33 Multiplicom N.V. Company Overview 76
5.33.1 Multiplicom N.V. Pipeline Products & Ongoing Clinical Trials Overview 76
5.34 Myriad Genetics, Inc. Company Overview 78
5.34.1 Myriad Genetics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 78
5.35 Natera, Inc. Company Overview 80
5.35.1 Natera, Inc. Pipeline Products & Ongoing Clinical Trials Overview 80
5.36 National University of Singapore Company Overview 85
5.36.1 National University of Singapore Pipeline Products & Ongoing Clinical Trials Overview 85
5.37 NewGene Ltd Company Overview 89
5.37.1 NewGene Ltd Pipeline Products & Ongoing Clinical Trials Overview 89
5.38 NX PharmaGen Inc. Company Overview 94
5.38.1 NX PharmaGen Inc. Pipeline Products & Ongoing Clinical Trials Overview 94
5.39 Paragon Medical, Inc. Company Overview 95
5.39.1 Paragon Medical, Inc. Pipeline Products & Ongoing Clinical Trials Overview 95
5.40 Population Diagnostics Inc. Company Overview 96
5.40.1 Population Diagnostics Inc. Pipeline Products & Ongoing Clinical Trials Overview 96
5.41 Qiagen N.V. Company Overview 100
5.41.1 Qiagen N.V. Pipeline Products & Ongoing Clinical Trials Overview 100
5.42 Quantamerix Company Overview 102
5.42.1 Quantamerix Pipeline Products & Ongoing Clinical Trials Overview 102
5.43 Sapien Biosciences Company Overview 103
5.43.1 Sapien Biosciences Pipeline Products & Ongoing Clinical Trials Overview 103
5.44 Seegene, Inc. Company Overview 104
5.44.1 Seegene, Inc. Pipeline Products & Ongoing Clinical Trials Overview 104
5.45 Sequenom, Inc. Company Overview 106
5.45.1 Sequenom, Inc. Pipeline Products & Ongoing Clinical Trials Overview 106
5.46 Stanford University Company Overview 112
5.46.1 Stanford University Pipeline Products & Ongoing Clinical Trials Overview 112
5.47 The Johns Hopkins University Company Overview 114
5.47.1 The Johns Hopkins University Pipeline Products & Ongoing Clinical Trials Overview 114
5.48 The Sheba Medical Center Company Overview 115
5.48.1 The Sheba Medical Center Pipeline Products & Ongoing Clinical Trials Overview 115
5.49 The University of Utah Company Overview 116
5.49.1 The University of Utah Pipeline Products & Ongoing Clinical Trials Overview 116
5.50 TrovaGene, Inc. Company Overview 117
5.50.1 TrovaGene, Inc. Pipeline Products & Ongoing Clinical Trials Overview 117
5.51 University of Colorado Company Overview 121
5.51.1 University of Colorado Pipeline Products & Ongoing Clinical Trials Overview 121
5.52 University of Washington Company Overview 122
5.52.1 University of Washington Pipeline Products & Ongoing Clinical Trials Overview 122
5.53 VitaPath Genetics, Inc. Company Overview 123
5.53.1 VitaPath Genetics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 123
5.54 Xiamen Zeesan Biotech Co.,Ltd Company Overview 124
5.54.1 Xiamen Zeesan Biotech Co.,Ltd Pipeline Products & Ongoing Clinical Trials Overview 124
5.55 Yale University Company Overview 125
5.55.1 Yale University Pipeline Products & Ongoing Clinical Trials Overview 125
6 Inborn Gene or Chromosome Alterations- Recent Developments 126
7 Appendix 165
7.1 Methodology 165
7.2 About GlobalData 167
7.3 Contact Us 168
7.4 Disclaimer 168


【レポート販売概要】

■ タイトル:世界における先天的遺伝子変異または先天的染色体変異検査製品のパイプライン動向2015
■ 英文:Inborn Gene or Chromosome Alterations - Pipeline Review, 2015
■ 発行日:2015年10月1日
■ 調査会社:GlobalData
■ 商品コード:GDME0076EPD
■ 調査対象地域:グローバル
  • 固定衛星業務(FSS)の世界市場2016-2020
    About FSS An FSS is a type of service that uses geosynchronous satellites to broadcast through TV and radio, telecommunications, and satellite communication that are used by governments, military organizations, small and large enterprises, and other end-users. It can provide information to intelligence and security organizations. FSS is classified into wholesale services and managed services. The …
  • Ellex Medical Lasers Limited:市場シェア分析
    Ellex Medical Lasers Limited Market Share Analysis Summary GlobalData’s new report, “Ellex Medical Lasers Limited Market Share Analysis” provides in-depth information on Ellex Medical Lasers Limited .’s market position in the different medical equipment markets it operates in. The report provides Ellex Medical Lasers Limited market share information in two key market categories – Ophthalmic Diagno …
  • 航空貨物セキュリティおよびスクリーニングシステム市場(2014-2024)
    Following the tragic events of September 11 2001, much attention has been focused on improving aviation security by developing regulations and integrating new technologies to reduce the potential threats from terrorist activities. For the most part, security arrangements (regulations and technologies) have been concentrated on the area of passenger travel. The recent failed attempt to plant bombs …
  • 世界のCAD(Computer-aided Design)市場動向(2012-2016)
    Introduction to the market Computer-aided design (CAD) software provides an efficient, easier and cost-effective method for modeling and designing critical parts, components, and structurals with enhanced quality and accuracy. These software solutions assist engineers, architects, and other design professionals to draft industry-specific products for superior product development, thereby facilitat …
  • 負圧創傷治療の世界市場分析:製品別(従来型、シングルユース)、傷別(糖尿病性足潰瘍、圧迫潰瘍、静脈脚潰瘍、火傷)、エンドユーザー別(病院、ホームケア)、セグメント予測、2014-2025
    The global negative pressure wound therapy (NPWT) market is anticipated to reach a value of USD 4.0 billion by 2025, according to a new report by Grand View Research, Inc. Increasing awareness in the developing regions pertaining to advanced wound care is providing a significant opportunity to the key market players to cater to the unmet needs of the target population. The primary driver associate …
  • 低悪性度リンパ腫:世界の臨床試験レビュー(2014年上半期)
    Indolent Lymphoma Global Clinical Trials Review, H1, 2014 Summary GlobalData's clinical trial report, “Indolent Lymphoma Global Clinical Trials Review, H1, 2014" provides data on the Indolent Lymphoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Indolent Lymphoma. It includes an overview of the trial numbers and their recruitment s …
  • 世界の屋内無線(ワイヤレス)市場動向、分析及び予測(2014-2019):システム別、事業別、ビルのサイズ別分析
    In-building wireless solution refers to a set of products, services, utilized to build an in-building network for reliable and seamless indoor coverage. The in-building wireless solutions assist in creating a more engaging business environment with no dropped calls and high speed data connections. Overall, it supports organizations to deal with multiple factors such as, coverage, capacity, scalabi …
  • 金属製包装容器の世界市場:金属製缶、金属製キャップ/クロージャ、金属製バレル/ドラム
    The demand for metal packing has increased significantly in recent times; particularly because of the increasing demand for packaged food. The tremendous increase in the consumption of canned food is the driving force of many countries and companies, especially in the emerging economies such as China and India. Major metal packaging associations are focusing on spreading awareness about metal pack …
  • ICT予算及び人員配置動向:製造産業部門 – 企業のICT投資計画
    Why was the report written? In order to provide a depth of insight into ICT vendors’ and service providers’ potential customers. What is the current market landscape and what is changing? ICT expenditure was always overlooked as an expense in the manufacturing industry. With business process streamlining as a key priority, manufacturers are increasing their ICT spending to improve their operationa …
  • クラウドCDN(コンテンツデリバリネットワーク)の世界市場予測(~2021)
    MarketsandMarkets forecasts the Cloud Content Delivery Network market size to grow from USD 1.81 Billion in 2016 to USD 6.23 Billion by 2021, at an estimated Compound Annual Growth Rate (CAGR) of 28.0%. Major factors contributing to the growth of the cloud CDN market are growing rich media file contents, video content, increasing use of connected and smart devices, and proliferation of rich media …
  • 地球温暖化と保険業界:Global Warming & the Insurance Industry
    Global warming refers to the increase in the average temperature of the Earth's near-surface air and oceans in recent decades and its projected continuation. Though it is difficult to connect specific weather events to global warming, an increase in global temperatures may in turn cause other changes, including glacial retreat and worldwide sea level rise. Changes in the amount and pattern of prec …
  • グローバル軍事用装甲・対IED防御車両市場(2014-2024)
    Summary The Global Armored And Counter IED Vehicles Market 2014-2024 Report, published by Strategic Defence Intelligence, provides readers with a detailed analysis of both historic and forecast global industry values, factors influencing demand, the challenges faced by industry participants, analysis of industry leading companies, and key news. Key Findings - The global armored and counter IED veh …
  • 世界のアナログIC市場動向(2014~2018)
    TechNavio's analysts forecast the Global Analog IC market to grow at a CAGR of 4.79 percent over the period 2013-2018. One of the key factors contributing to this market growth is the need for power management in electronic products. The Global Analog IC market has also been witnessing the emerging applications of analog ICs in LED lighting systems. However, the demand and supply imbalance of anal …
  • 注射可能薬剤送達の世界市場予測(~2021年)
    The global injectable drug delivery market, in terms of value, is projected to reach USD 624.50 billion by 2021 from USD 362.38 billion in 2016, at a CAGR of 11.5% during the forecast period. The increase in the use of biologics, the increase in the prevalence of chronic diseases, the increasing occurrence of needlestick injuries, and the benefits of injections (convenience, ease of use, and reduc …
  • 主要先進国における全身性乾癬治療薬市場(~2020)
    Systemic Psoriasis Therapeutics in Major Developed Markets to 2020 - Continued Uptake of Biologics and Novel Pipeline Drugs to Drive Growth Summary GBI Research has released its pharma report “Systemic Psoriasis Therapeutics in Major Developed Markets to 2020 - Continued Uptake of Biologics and Novel Pipeline Drugs to Drive Growth”. The systemic psoriasis market is forecast to grow substantially o …
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。